Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
about
Triglyceride-rich lipoproteins as a causal factor for cardiovascular diseaseUse of fibrates in the metabolic syndrome: A reviewEffects of serum lipoproteins on cyclosporine A cellular uptake and renal toxicity in vitroFenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial.Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesityEffects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy.Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.A fish a day, keeps the cardiologist away! - A review of the effect of omega-3 fatty acids in the cardiovascular system.Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment.AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed.Molecular effect of fenofibrate on PBMC gene transcription related to lipid metabolism in patients with metabolic syndrome.
P2860
Q26745946-9A47F5EF-7B8A-4BA2-B28E-373C2F3A1449Q26765234-EBAC2120-1FFC-4034-801C-A79B00E66F8CQ28580552-FF87ABA2-97CC-4B0B-9DAD-098AA97D7496Q33577851-B4966CC5-EF83-4142-8FA4-D079BE02F5D8Q33905661-11D084A7-0C9C-492E-BACE-70E23E92D86EQ33933474-810AA345-3B39-4D19-BC8C-2C8592C6F429Q34360091-43AC01D9-7B1C-493B-950F-D0B890AC0BD4Q34662589-A853D269-E54E-41FC-B625-8AD7D0588F5BQ35683911-945A361B-C40B-4B46-8EE2-DB7B1FB010A2Q36419283-30B98A0F-624A-43FC-A5CD-6AABF1B0AD03Q37015975-09760D7A-86F0-40AB-8AA3-353274A29867Q37653029-29E5D2D9-2073-4D15-AD99-0EA4FBB55B0AQ37731877-9054A057-99F6-413D-AB9A-5ABF843B9A0EQ37851958-43978CF2-CF5B-4728-BEF4-06B487373565Q43118874-BCB34EB7-515D-42DC-821A-5863CF9B0EB0Q48174139-755C84AA-4D27-4E64-ACA1-3AC3ACD686F6
P2860
Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Update on the clinical utility ...... tion and rational prescribing.
@en
Update on the clinical utility ...... tion and rational prescribing.
@nl
type
label
Update on the clinical utility ...... tion and rational prescribing.
@en
Update on the clinical utility ...... tion and rational prescribing.
@nl
prefLabel
Update on the clinical utility ...... tion and rational prescribing.
@en
Update on the clinical utility ...... tion and rational prescribing.
@nl
P2860
P921
P356
P1476
Update on the clinical utility ...... tion and rational prescribing.
@en
P2093
Michel Farnier
P2860
P304
P356
10.2147/VHRM.S3390
P407
P577
2008-01-01T00:00:00Z